Volpato Giovanni, Compagnucci Paolo, Cipolletta Laura, Parisi Quintino, Valeri Yari, Carboni Laura, Giovagnoni Andrea, Dello Russo Antonio, Casella Michela
Cardiology and Arrhythmology Clinic, University Hospital "Ospedali Riuniti", Ancona, Italy.
Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
Front Cardiovasc Med. 2022 Aug 22;9:870001. doi: 10.3389/fcvm.2022.870001. eCollection 2022.
Catheter ablation (CA) is a fundamental therapeutic option for the treatment of recurrent ventricular arrhythmias. Notwithstanding the tremendous improvements in the available technology and the increasing amount of evidence in support of CA, in some patients the procedure fails, or is absolutely contraindicated due to technical or clinical issues. In these cases, the clinical management of patients is highly challenging, and mainly involves antiarrhythmic drugs escalation. Over the last 5 years, stereotactic arrhythmia radioablation (STAR) has been introduced into clinical practice, with several small studies reporting favorable arrhythmia-free outcomes, without severe side effects at a short to mid-term follow-up. In the present systematic review, we provide an overview of the available studies on stereotactic arrhythmia radioablation, by describing the potential indications and technical aspects of this promising therapy.
导管消融术（CA）是治疗复发性室性心律失常的一种基本治疗选择。尽管现有技术有了巨大进步，且支持CA的证据越来越多，但在一些患者中，该手术仍会失败，或者由于技术或临床问题而绝对禁忌。在这些情况下，患者的临床管理极具挑战性，主要涉及抗心律失常药物的升级。在过去5年中，立体定向心律失常射频消融术（STAR）已引入临床实践，几项小型研究报告了良好的无心律失常结局，在短期至中期随访中无严重副作用。在本系统评价中，我们通过描述这种有前景的治疗方法的潜在适应证和技术方面，对立体定向心律失常射频消融术的现有研究进行了综述。
